

## BIBLIOGRAFÍA

---

1. González R, Campins M, Rodrigo JA, Uriona D, Vilca LM. Influenza vaccination coverage in children with risk conditions in Catalonia. *Enferm Infecc Microbiol Clin*. 2015;33:22-6.
2. Arístegui Fernández J, Pérez-Yarza EG, Mellado Peña MJ, Rodrigo Gonzalo de Liria C, Hernández Sampelayo T, García García JJ, *et al.*, en representación del grupo de estudio HOSPIGRIP. Hospitalizaciones infantiles asociadas a infección por virus influenza en seis ciudades de España (2014-2016). *An Pediatr (Barc)* 2018; Jul 25. pii: S1695-4033(18)30300-X.
3. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. Geneva: WHO; Mar 2018. Disponible en: [http://www.who.int/influenza/vaccines/virus/recommendations/2018\\_19\\_north/en/](http://www.who.int/influenza/vaccines/virus/recommendations/2018_19_north/en/) (último acceso: 10 Oct 2018).
4. Ministerio de Sanidad, Consumo y Bienestar Social. Vacunación en trabajadores sanitarios. Disponible en: [https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Vacunacion\\_sanitarios.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Vacunacion_sanitarios.pdf) (último acceso: 10 Oct 2018).
5. American Academy of Pediatrics. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2018-2019. *Pediatrics*. 2018;Sep 3. pii: e20182367. doi: 10.1542/peds.2018-2367.
6. Ministerio de Sanidad, Consumo y Bienestar Social. Vacunación en grupos de riesgo de todas las edades y en determinadas situaciones. Disponible en: <https://www.mscbs.gob.es/fr/profesionales/saludPublica/prevPromocion/vacunaciones/GruposRiesgo.htm> (último acceso: 10 Oct 2018).
7. Ministerio de Sanidad, Consumo y Bienestar Social. Recomendaciones de vacunación frente a la gripe. Temporada 2018-2019. Disponible en: [https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones\\_vacunacion\\_gripe.pdf](https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Recomendaciones_vacunacion_gripe.pdf) (último acceso: 10 Oct 2018).
8. Mårild K, Fredlund H, Ludvigsson JF. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. *Am J Gastroenterol*. 2010;105:2465-73.
9. Public Health England. Immunisation against infectious diseases. Immunisation of individuals with underlying medical conditions. The Green Book. Salisbury, Ramsay and Noakes eds. The Stationary Office. September 2016. Disponible en: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/566853/Green\\_Book\\_Chapter7.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/566853/Green_Book_Chapter7.pdf) (último acceso: 10 Oct 2018).
10. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, *et al.* Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis*. 2014;58:309-18.
11. Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. *Curr Opin Infect Dis*. 2016;29:319-29.
12. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB, *et al.*; US Department of Health and Human Services/Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2018-19 influenza season. *MMWR*. 2018;67:1-20.
13. Comité Asesor de Vacunas de la Asociación Española de Pediatría. Fichas técnicas de vacunas antigripales. Disponible en: <http://vacunasaep.org/profesionales/fichas-tecnicas-vacunas/resultados?diseases=148> (último acceso: 10 Oct 2018).
14. Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P, Keyserling H, *et al.* Safety and immunogenicity of full-dose trivalent inactivated influenza vaccine (TIV) compared with half-dose TIV administered to children 6 through 35 months of age. *J Pediatr Infect Dis Soc*. 2015;4:214-24.
15. Jain VK, Domachowske JB, Wang L, *et al.* Time to change dosing of inactivated quadrivalent influenza vaccine in young children: evidence from a Phase III, randomized, controlled trial. *J Pediatric Infect Dis Soc*. 2017;6:9-19.

16. Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, *et al.* Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. *Pediatrics*. 2011;128:e276-89.
17. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. *Hum Vaccin Immunother*. 2012;8:81-8.
18. García A, Fernandez Prada M, Aristegui J, Moreno D, Redondo E, Jimeno I, *et al.* Documento de actualización y reflexión sobre vacunación antigripal en España. Disponible en: <https://vacunasaep.org/profesionales/noticias/gripe-consenso-sscc-2018> (último acceso: 10 Oct 2018).
19. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza in Europe. Disponible en: <https://ecdc.europa.eu/en/seasonal-influenza> (último acceso: 10 Oct 2018).
20. European Centre for Disease Prevention and Control (ECDC)-WHO Regional Office for Europe/Europe weekly influenza update. *Flu News Europe*. Week /2018 (14-20 May 2018). Disponible en: <http://flunewseurope.org/Archives> (último acceso: 10 Oct 2018).
21. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Informe de Vigilancia de la Gripe en España Temporada 2017-2018 (Desde la semana 40/2016 hasta la semana 20/2017). Disponible en: [http://vgripe.isciii.es/documentos/20172018/InformesAnuales/Informe\\_Vigilancia\\_GRIPE\\_2017-2018\\_27julio2018.pdf](http://vgripe.isciii.es/documentos/20172018/InformesAnuales/Informe_Vigilancia_GRIPE_2017-2018_27julio2018.pdf) (último acceso: 10 Oct 2018).
22. Reina J. Las vacunas cuadrivalentes frente a la gripe estacional. ¿Son la solución definitiva? *Med Clin (Barc)*. 2014;142:355-7.
23. Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. *Expert Rev Vaccines*. 2012;11:1293-303.
24. Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of a inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. *Pediatr Infect Dis J*. 2014;33:630-6.
25. Public Health England (PHE). National flu immunization programme plan. Disponible en: <https://www.gov.uk/government/publications/national-flu-immunisation-programme-plan> (último acceso: 10 Oct 2018).
26. National Institute for Health and Welfare, Finland. Vaccination. Disponible en: <https://thl.fi/en/web/vaccination> (último acceso: 10 Oct 2018).
27. Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI) Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2018-2019. Disponible en: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2018-2019.html> (último acceso: 10 Oct 2018).
28. NSW Government, Health. Seasonal influenza vaccination 2018-2019. Disponible en: [https://www.health.nsw.gov.au/immunisation/pages/seasonal\\_flu\\_vaccination.aspx](https://www.health.nsw.gov.au/immunisation/pages/seasonal_flu_vaccination.aspx) (último acceso: 10 Oct 2018).
29. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. *Vaccine*. 2012;30:886-92.
30. Public Health England (PHE). Annual flu programme. Disponible en: <https://www.gov.uk/government/collections/annual-flu-programme> (último acceso: 10 Oct 2018).
31. Perez-Rubio A, Eiros JM. Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain. *Rev Esp Quimioter*. 2018;31:43-52.
32. Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England. *BMC Med*. 2017;15:166.
33. Public Health England. Seasonal influenza vaccine uptake in GP patients: winter season 2017 to 2018. Disponible en: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/710416/Seasonal\\_influenza\\_vaccine\\_uptake\\_in\\_GP\\_patients\\_winter\\_season\\_2017\\_to\\_2018..pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/710416/Seasonal_influenza_vaccine_uptake_in_GP_patients_winter_season_2017_to_2018..pdf) (último acceso: 10 Oct 2018).
34. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, *et al.* Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed

- influenza in primary care in the United Kingdom: 2015/16 end-of-season results. *Euro Surveill.* 2016;21(38):pii=30348.
35. Pebody R, Sile B, Warburton F, Sinnathamby M, Tsang C, Zhao H, Ellis J, *et al.* Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. *Eurosurveill.* 2017;22(4).pii:30450.
  36. Public Health England (PHE) Influenza vaccine effectiveness (VE) in adults and children in primary care in the United Kingdom (UK): provisional end-of- season results 2017-18. Disponible en: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/726342/Influenza\\_vaccine\\_effectiveness\\_in\\_primary\\_care\\_2017\\_2018.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/726342/Influenza_vaccine_effectiveness_in_primary_care_2017_2018.pdf) (último acceso: 10 Oct 2018).
  37. Nohynek H, Baum U, Syrjänen R, Ikonen N, Sundman J, Jokinen J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. *Euro Surveill.* 2016;21:pii=30346.
  38. Nohynek H. Universal vaccination of children. The Finnish approach. Disponible en: <http://eswi.org/ippc/wp-content/uploads/sites/14/2017/06/8-Nohynek.pdf>. ESWI Leuven 14 June 2017. (Último acceso: 10 Oct 2018).
  39. Flannery B, Reynolds SB, Blanton L, Santibanez TA, O'Halloran A, Lu PJ, *et al.* Influenza vaccine effectiveness against pediatric deaths: 2010-2014. *Pediatrics.* 2017;139:pii:e20164244.
  40. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. *Pediatr Infect Dis J.* 2011;30:e24-8.
  41. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, *et al.* The underrecognized burden of influenza in young children. *N Engl J Med.* 2006;355:31-40.
  42. Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, *et al.* Influenza-associated pediatric deaths in the United States, 2004-2012. *Pediatrics.* 2013;132:796-804.
  43. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. *N Engl J Med.* 1978;298:587-92.
  44. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. *Pediatr Infect Dis J.* 1997;16:1065-8.
  45. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. *J Infect Dis.* 1981;144:433-41.
  46. Loeb M, Russell ML, Manning V, Fonseca K, Earn D, Horsman G, *et al.* Live attenuated versus inactivated Influenza vaccine in Hutterite children: a cluster randomized blinded trial. *Ann Intern Med.* Published online 16 August 2016. Disponible en: <http://annals.org/article.aspx?articleid=2543271> (último acceso: 10 Oct 2018).
  47. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. *N Engl J Med.* 2001;344:889-96.
  48. Charu V, Viboud C, Simonsen L, Sturm-Ramirez K, Shinjoh M, Chowell G, *et al.* Influenza-related mortality trends in Japanese and American seniors: evidence for the indirect mortality benefits of vaccinating schoolchildren. *PLoS One.* 2011;6:e26282.
  49. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, *et al.* Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. *JAMA.* 2010;303:943-50.
  50. Kim TH. Seasonal influenza and vaccine herd effect. *Clin Exp Vacc Research.* 2014;3:128-32.
  51. Glezen WP, Gaglani MJ, Kozinetz CA, Piedra PA. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. *J Infect Dis.* 2010;202:1626-33.
  52. Cohen SA, Chui KK, Naumova EN. Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002-2006. *J Am Geriatr Soc.* 2011;59:327-32.
  53. Mertz D, Fadel SA, Lam PP, Tran D, Srigley JA, Asner SA, *et al.* Herd effect from influenza vaccination in non-healthcare settings: a systematic review of randomised controlled

- trials and observational studies. *Euro Surveill.* 2016;21(42).
54. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. *PLoS Med.* 2013;10:e1001527.
  55. Pitman RJ, White LJ, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. *Vaccine.* 2012;30:1208-24.
  56. Eichner M, Schwehm M, Eichner L, Gerlier L. Direct and indirect effects of influenza vaccination. *BMC Infect Dis.* 2017;17(1):308.
  57. Alguacil-Ramos AM, Garrigues-Pelufo TM, Muelas-Tirado J, Portero-Alonso A, Pérez-Panadés J, Fons-Martínez J. Seguridad de las vacunas antigripales en grupos de riesgo: análisis de las sospechas de reacciones adversas notificadas en Comunidad Valenciana entre 2005 y 2011. *Rev Esp Quimioter.* 2015;28:193-9.
  58. Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015. *Vaccine.* 2016;34:2507-12.
  59. Baxter R, Eaton A, Hansen J, Aukes L, Caspard H, Ambrose CS. Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49 years. *Vaccine.* 2017;35:1254-8.
  60. Wood NJ, Blyth CC, Willis GA, Richmond P, Gold MS, BATTERY JP, *et al.* The safety of seasonal influenza vaccines in Australian children in 2013. *Med J Aust.* 2014;201:596-600.
  61. Li-Kim-Moy J, Yin JK, Rashid H, Khandaker G, King C, Wood N, *et al.* Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. *Euro Surveill.* 2015;20(24):pii=21159.
  62. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. *Vaccine.* 2012;30:2024-31.
  63. Kawai AT, Martin D, Kulldorff M, Li L, Cole DV, McMahon-Walraven CN, *et al.* Febrile seizures after 2010-2011 trivalent inactivated influenza vaccine. *Pediatrics.* 2015;136:e848-55.
  64. Kroger AT, Duchin J, Vázquez M. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2017. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf> (último acceso: 10 Oct 2018).
  65. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. *Clin Infect Dis.* 2014;58:1149-55.
  66. Feltelius N, Persson I, Ahlqvist-Rastad J, Andersson M, Arnheim-Dahlström L, Bergman P, *et al.* A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden. *J Intern Med.* 2015;278:335-53.
  67. Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, *et al.* Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. *Sci Transl Med.* 2015;7:294ra105.
  68. Echeverría Zudaire L, Ortigosa del Castillo L, Alonso Lebrero E, Álvarez García FJ, Cortés Álvarez N, García Sánchez N, *et al.* Documento de consenso sobre la actitud ante un niño con una reacción alérgica tras la vacunación o alergia a componentes vacunales. Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica (SEICAP) y Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP). *An Pediatr (Barc).* 2015;83:63.e1-10.
  69. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, *et al.* Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol.* 2016;137:868-78.
  70. Hamiel U, Kventsel I, Youngster I. Recurrent immune thrombocytopenia after influenza vaccination: A case report. *Pediatrics.* 2016;138(6).pii:e20160124.

71. Kelso JM. Drug and vaccine allergy. *Immunol Allergy Clin North Am.* 2015;35:221-30.
72. Des Roches A, Samaan K, Graham F, Lacombe-Barrios J, Paradis J, Paradis L, *et al.* Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. *J Allergy Clin Immunol Pract.* 2015;3:138-9.
73. Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, SNIFFLE Study Investigators. Safety of live attenuated influenza vaccine in atopic children with egg allergy. *J Allergy Clinical Immunol.* 2015;136:376-81.
74. Sakala IG, Honda-Okubo Y, Fung J, Petrovsky N. Influenza immunization during pregnancy: Benefits for mother and infant. *Hum Vaccin Immunother.* 2016;12:3065-71.
75. Martin A, Cox S, Jamieson DJ, Whiteman MK, Kulkarni A, Tepper NK. Respiratory illness hospitalizations among pregnant women during influenza season, 1998-2008. *Matern Child Health J.* 2013;17:1325-31.
76. Mazagatos C, Delgado-Sanz C, Oliva J, Gherasim A, Larrauri A; Spanish Influenza Surveillance System. Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16. *PLoS One.* 2018;13(8):e0200934.
77. Vilca LM, Verma A, Bonati M, Campins M. Impact of influenza on outpatient visits and hospitalizations among pregnant women in Catalonia, Spain. *J Infect.* 2018 Jul 5. pii: S0163-4453(18)30211-1.
78. McMillan M, Porritt K, Kralik D, Costi L, Marshall H. Influenza vaccination during pregnancy: a systematic review of fetal death, spontaneous abortion, and congenital malformation safety outcomes. *Vaccine.* 2015;33:2108-17.
79. Waller DK, Hashmi SS, Hoyt AT, Duong HT, Tinker SC, Gallaway MS; National Birth Defects Prevention Study. Maternal report of fever from cold or flu during early pregnancy and the risk for noncardiac birth defects, National Birth Defects Prevention Study, 1997-2011. *Birth Defects Res.* 2018;110(4):342-51.
80. Borren I, Tambs K, Gustavson K, Schjølberg S, Eriksen W, Håberg SE, *et al.* Early prenatal exposure to pandemic influenza A (H1N1) infection and child psychomotor development at 6 months - A population-based cohort study. *Early Hum Dev.* 2018;122:1-7.
81. Nunes MC, Aqil AR, Omer SB, Madhi SA. The effects of influenza vaccination during pregnancy on birth outcomes: A Systematic Review and Meta-Analysis. *Am J Perinatal.* 2016;33:1104-14.
82. Nunes MC, Madhi SA. Influenza vaccination during pregnancy for prevention of influenza confirmed illness in the infants: a systematic review and meta-analysis. *Hum Vaccin Immunother.* 2017 Jul 14:0. doi: 10.1080/21645515.2017.1345385.
83. Nunes MC, Cutland CL, Jones S, Downs S, Weinberg A, Ortiz JR, *et al.* Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: Results from a randomized controlled trial. *Clin Infect Dis.* 2017 May 29. doi: 10.1093/cid/cix497.
84. Asavapiriyant S, Kittikraisak W, Suntarattiwong P, Ditsungnoen D, Kaoiean S, Phadungkiatwatana P, *et al.* Tolerability of trivalent inactivated influenza vaccine among pregnant women, 2015. *BMC Pregnancy Childbirth.* 2018;18(1):110.
85. Moro P, Baumblatt J, Lewis P, Cragan J, Tepper N, Cano M. Surveillance of adverse events after seasonal influenza vaccination in pregnant women and their infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016. *Drug Saf.* 2017;40:145-52.
86. Zerbo O, Qian Y, Yoshida C, Fireman BH, Klein NP, Croen LA. Association between influenza infection and vaccination during pregnancy and risk of autism spectrum disorder. *JAMA Pediatr.* 2017;171:e163609.
87. Kharbanda EO, Vazquez-Benitez G, Romitti PA, Naleway AL, Cheetham TC, Lipkind HS, *et al.* Vaccine Safety Datalink. First trimester influenza vaccination and risks for major structural birth defects in offspring. *J Pediatr.* 2017;187:234-239.e4.
88. Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, *et al.* Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. *Vaccine.* 2017;35:5314-22.
89. Sperling RS, Riley LE; Immunization and Emerging Infections Expert Work Group. Influenza vaccination, pregnancy safety, and

- risk of early pregnancy\_loss. *Obstet Gynecol.* 2018;131(5):799-802.
90. Regan AK, Moore HC, Sullivan SG. Does influenza vaccination during early pregnancy really increase the risk of miscarriage? *Vaccine.* 2018;36(17):2227-8.
91. Sukumaran L, McCarthy NL, Kharbanda EO, Vazquez-Benitez G, Lipkind HS, *et al.* Infant hospitalizations and mortality after maternal vaccination. *Pediatrics.* 2018 Feb 20. pii: e20173310. doi: 10.1542/peds.2017-3310.
92. Vila-Candel R, Navarro-Illana P, Navarro-Illana E, Castro-Sánchez E, Duke K, Soriano-Vidal FJ, *et al.* Determinants of seasonal influenza vaccination in pregnant women in Valencia, Spain. *BMC Public Health.* 2016;16:1173.
93. Comité Asesor de Vacunas de la AEP. Coberturas vacunales en España-2017 (segunda parte). Disponible en: <https://vacunasaep.org/profesionales/noticias/cobertura-espana-2017-parte2> (último acceso: 10 Oct 2018).
94. Barber A, Muscoplat MH, Fedorowicz A. Coverage with tetanus, diphtheria, and acellular pertussis vaccine and influenza vaccine among pregnant women - Minnesota, March 2013-December 2014. *MMWR Morb Mortal Wkly Rep.* 2017;66:56-9.
95. Vilca ML, Esposito S. The crucial role of maternal care providers as vaccinators for pregnant women. *Vaccine.* 2017 Aug 16. pii: S0264-410X(17)31084-8.
96. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination in Europe. Disponible en: <https://ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-europe> (último acceso: 10 Oct 2018).
97. Encuesta 2012-2013: ¿Los pediatras nos vacunamos de la gripe? Disponible en: <http://vacunasaep.org/resultados-de-la-encuesta-vacgripe-2012> (último acceso: 10 Oct 2018).
98. Arrazola P, Benavente S, De Juanes JR, García de Codes A, Gil P, Jaén F, *et al.* Cobertura vacunal antigripal de los trabajadores de un hospital general, 2004-2011. *Vacunas.* 2012;13:138-44.
99. Wang TL, Jing L, Bocchini JA Jr. Mandatory influenza vaccination for all healthcare personnel: a review on justification, implementation and effectiveness. *Curr Opin Pediatr.* 2017;29:606-5.
100. Lukich N, Kekewich M, Roth V. Should influenza vaccination be mandatory for healthcare workers? *Healthc Manage Forum.* 2018;31:214-7.
101. Iacobucci G. NHS staff who refuse flu vaccine this winter will have to give reasons. *BMJ.* 2017;359:j4766.
102. Carter AH, Yentis SM. Ethical considerations in the uptake of influenza vaccination by healthcare workers. *Public Health.* 2018;158:61-3.
103. Hulo S, Nuvoli A, Sobaszek A, Salembier-Trichard A. Knowledge and attitudes towards influenza vaccination of health care workers in emergency services. *Vaccine.* 2017;35:205-7.

## AUTORES Y FILIACIONES

---

### Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP) 2018

**David Moreno-Pérez** (DMP). Infectología Pediátrica e Inmunodeficiencias. Unidad de Gestión Clínica de Pediatría. Hospital Materno-Infantil. Hospital Regional Universitario de Málaga. Grupo de Investigación IBIMA. Departamento de Pediatría y Farmacología. Facultad de Medicina de la Universidad de Málaga.

**Nuria García Sánchez** (NGS). Pediatra. Centro de Salud Delicias Sur. Zaragoza. Profesora Asociada en Ciencias de la Salud. Departamento de Pediatría. Facultad de Medicina de la Universidad de Zaragoza.

**Jesús Ruiz-Contreras** (JRC). Servicio de Pediatría. Hospital Universitario 12 de octubre. Madrid. Departamento de Pediatría. Facultad de Medicina de la Universidad Complutense de Madrid.

**Javier Álvarez Aldeán** (JAA). Pediatra. Jefe de Servicio de Pediatría. Hospital Costa del Sol. Marbella. Málaga.

**Francisco José Álvarez García** (FJAG). Pediatra. Centro de Salud de Llanera. Asturias. Profesor Asociado en Ciencias de la Salud. Departamento de Medicina. Universidad de Oviedo.

**María José Cilleruelo Ortega** (MJCO). Servicio de Pediatría. Hospital Universitario Puerta de Hierro-Majadahonda, Madrid. Departamento de Pediatría. Facultad de Medicina de la Universidad Autónoma de Madrid.

**María Garcés-Sánchez** (MGS). Pediatra. Centro de Salud Nazaret. Valencia. Investigadora adscrita al Área de Vacunas. FISABIO. Valencia.

**Ángel Hernández Merino** (AHM). Pediatra. Centro de Salud La Rivota. Alcorcón. Madrid.

**María Méndez Hernández** (MMH). Pediatra. Coordinadora de la Unidad de enfermedades infecciosas. Hospital Germans Trias i Pujol. Badalona, Barcelona. Profesora Asociada de Pediatría de la Facultad de Medicina de la Universidad Autónoma de Barcelona.

**Manuel Merino Moína** (MMM). Pediatra. Centro de Salud El Greco. Getafe. Madrid. Madrid.

**Abián Montesdeoca Melián** (AMM). Pediatra. Centro de Salud de Guanarteme. Las Palmas de Gran Canaria.

## ASESORÍA

---

Este documento ha contado con la asesoría interna de Javier Arístegui Fernández, Josep María Corretger Rauet y Luis Ortigosa del Castillo.

## FINANCIACIÓN

---

La elaboración de estas recomendaciones (análisis de los datos publicados, debate, consenso y publicación) no ha contado con ninguna financiación externa a la logística básica facilitada por la AEP.

## **CONFLICTOS DE INTERESES POTENCIALES DE LOS AUTORES (últimos 5 años)**

---

**DMP** ha colaborado en actividades docentes subvencionadas por Astra, Pfizer, GlaxoSmithKline, MSD y Sanofi Pasteur, como consultor en Advisory Board de GlaxoSmithKline y como investigador en ensayos clínicos de Novartis.

**NGS** ha colaborado en actividades docentes subvencionadas por MSD y Sanofi Pasteur y ha asistido a actividades docentes subvencionadas por Novartis y Pfizer.

**JRC** ha colaborado en actividades docentes subvencionadas por GlaxoSmithKline, MSD, Pfizer y Sanofi Pasteur y como investigador en ensayos clínicos de GlaxoSmithKline y Pfizer.

**JAA** ha colaborado en actividades docentes subvencionadas por Astra, GlaxoSmithKline, MSD, Pfizer y Sanofi Pasteur, y como consultor en Advisory Board de GlaxoSmithKline y Pfizer.

**FJAG** ha colaborado en actividades docentes subvencionadas por GlaxoSmithKline, MSD, Novartis, Pfizer y Sanofi Pasteur y como consultor en Advisory Board de GlaxoSmithKline y Novartis.

**MJCO** ha colaborado en actividades docentes subvencionadas por GlaxoSmithKline, MSD, Novartis, Pfizer y Sanofi Pasteur, como investigadora en ensayos clínicos de GlaxoSmithKline y Pfizer, y como consultora en Advisory Board de GlaxoSmithKline, MSD, Novartis, Pfizer y Sanofi Pasteur.

**MGS** ha colaborado en actividades docentes subvencionadas por Astra, GlaxoSmithKline, MSD Pfizer y Sanofi Pasteur, como consultora en Advisory Board de GlaxoSmithKline y Novartis, y como investigadora en ensayos clínicos de GlaxoSmithKline, Janssen, MSD y Sanofi Pasteur.

**AHM** ha recibido ayuda económica para asistir a actividades docentes nacionales, y ha participado en actividades docentes subvencionadas por Pfizer.

**MMH** ha colaborado como investigadora en ensayos clínicos de GlaxoSmithKline y Novartis.

**MMM** ha colaborado en actividades docentes subvencionadas por GlaxoSmithKline, MSD, Pfizer y Sanofi Pasteur, como investigador en ensayos clínicos de GlaxoSmithKline, MSD, Pfizer y Sanofi Pasteur y como consultor en Advisory Board de Novartis.

**AMM** ha recibido ayuda económica de Pfizer para asistir a actividades docentes nacionales e internacionales